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Dendritic NanoTechnologies, Inc.
It started with a passion for horticul- k
ture—for trees, in particular. Cou- d
pled with an interest in chemistry, a
this was the inspiration for Donald d
A. Tomalia, PhD, founder, president, r
and chief technical officer at Den- t
dritic NanoTechnologies, Inc. (DNT) m
in Mount Pleasant, MI. His goal was w
to find ways to make synthetic c
molecules and polymers that mim-
icked the appearance and growth of t
a growing tree, from trunk to branch D
to leaf. In 1979, Tomalia, then a re- S
search fellow at Dow Chemical, met 2
with success. He invented “den- t
drimers”—nanometer-sized, synthetic t
polymers in which constituent atoms e
are assembled in layered branches e
along a trunk of carbon atoms— d
which, when synthesized, do so in a
an extremely precise and controlled d
manner mirroring the growth pattern h
of a tree. Dendrimers’ very name de- h
rives from their appearance. In the a
Greek language, “dendri” translates p
into “tree,” and “meros” means i
“part of.” It has been an interesting s
25 years for dendrimers, and for c
Tomalia. Today, the word “den- M
drimer” appears as an official tech-
nical word in the American Heri-
tage Dictionary.
“Along the way, dendrimers went
from an interesting new discovery m
to a ten-year hiatus in the research pwasteland during the 1980s. “We
sreally touted dendrimers as some of
the most precise synthetic nano- t
scale structures known to man- akind,” recalls Tomalia, “but no one
dbelieved in the possibilities of den-
drimers for about ten years.” That I
changed in 1990 after he took a
ileave of absence from Dow and, in
1992, started a specialty polymer d
company called Dendritech. Pur- y
chased by Dow in 1998, Dendritech
introduced the first dendrimer-
based polymer product and fol-
lowed with 31 others. From 1998
Athrough 2001, Tomalia took his self-
oconfessed passion for dendrimers
“to the University of Michigan Medi-
pcal School, where he became the
ascientific director of the Center for
sBiologic Nanotechnology (CBN).
“We began to work on sharing our Rnow-how concerning the use of d
dendrimers for the targeting of ther-
tpeutic drugs, in particular cancer
“rugs,” says Tomalia of his collabo-
dative work with current CBN Direc-
bor, James R. Baker, Jr, M.D. CBN
taintains its own research efforts, in
thich it uses dendrimers as anti-
tancer therapeutics.
mIn 2001, Tomalia headed to Cen-
iral Michigan University and founded
tNT with seed money provided by
ntarpharma of Australia. In January
o005, Dow entered the scene again,
chis time by taking an equity posi-
tion in DNT and contributing an
ixtensive 196 U.S. and foreign pat-
Tnts. Of the 229 total U.S. den-
primer patents allowed, Dow held
sll the foundational patents for den-
arimer structure and synthesis and
sas transferred them to DNT. DNT
solds more than 30 additional
dctive or pending U.S. dendrimer
catents. So, dendrimers and—more
tmportantly from a commercial per-
lpective—the patents to commer-
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ritic NanoTechnologies, d
tnc., “but no one believed
t
n the possibilities of u




New Architectural Class c
f Polymer d
Nanotechnology is not new to the m
lanet,” says Tomalia. “It has been t
round for a few billion years ever r
ince nature created proteins, DNA, m
yNA—all very precise biologicallyerived nanostructures.” The den-
ritic nanoscale architecture is syn-
hetic and offers new possibilities.
But it took about 10 years for den-
rimers to catch on, largely helped
y initiatives such as the 2001 Na-
ional Nanotechnology Initiative and
he 21st Century National Nano-
echnology Research and Develop-
ent Act,” explains Tomalia, speak-
ng of the federal efforts to advance
he pace and diversity of nanotech-
ology research. The convergence
f this new dendrimer polymer ar-
hitecture with the worldwide nano-
echnology movement is currently
gniting all kinds of interest, says
omalia. “Now it has become ap-
arent there is a way to control
tructure precisely, almost atom by
tom, synthetically without the as-
istance of nature or biology” he
ays. According to Tomalia, den-
rimers are the fourth and most re-
ently discovered major architec-
ural class of polymers along with
inear, bridged, and branched mac-
omolecules. Tomalia, comparing
endrimers to elements of the peri-
dic table says dendrimer struc-
ures are fundamental nanoscale
uilding blocks for small-molecule
hemistry and biology. Dendrimers
re one of five dominating nano-
aterial building blocks; others are
uantum dots, carbon nanotubes,
ullerenes, and nanowires.
Dendrimers visually resemble a
luster of trees. By definition, a
endrimer is a group of two or more
endrons, or molecular trees. From
he trunk, the tree first splits into
wo branches. The process contin-
es at each branch terminus, creat-
ng a new branched array or gener-
tion and ultimately resulting in the
endritic pattern. Surface groups
re placed at the branch termini.
“The leaves are the surface groups
here we introduce the functional
hemical properties of a particular
endrimer,” says Tomalia. “We can
ake dendritic polymers out of all
ypes of materials—acrylates, sty-
enes, amino acids—practically any
onomer or small organic reagent
ou can think of,” he says. All den-
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500dritic polymers are open, covalent r
assemblies of branch cells. Pres- a
bently, more than 100 different den-
drimer compositions and more than c
s1,000 kinds of surface chemistries
are known. The dendritic architec- p
dture is divided into four general
classes: random hyperbranched poly- l
mmers, dendrigraft polymers, dendrons,
and dendrimers. Dendrons and den- B
drimers are the most intensely in- t
svestigated subsets of dendritic
polymers. b
pThe ultimate size of a dendrimer
is predetermined by the number of s
cgenerations synthesized and the
type of functional surface groups T
wadded to the outermost canopy of
leaves created. Precise mathemat- n
iics predict how many branches will
be created with each generation
gand how many leaves or surface
functional groups will be present at h
ieach generation. This allows re-
searchers to predict the molecular p
aweight at each branching. “The size
of a dendrimer is dependent on the h
tnumber of generations created
around the core,” explains Tomalia. d
aFor the polyamidoamine (PAMAM)-
based dendrimer series, the funda- t
Tmental dendrimer series created by
Tomalia and DNT, each generation R
Ugrows one nanometer in diameter.
DNT researchers can make 9- to 10- P
Bgeneration dendrimers for a total
size of 10 nm. PAMAM dendrimers s
pconstitute the first dendrimer family
commercialized as well as the most t
textensively characterized and best
understood. c
Nanoscale Trojan Horses
A dendrimer’s canopy of leaves de-
fines an empty interior space or
void. “We are coming up with novel
approaches to drug delivery using
this empty space,” explains Tom-
alia. “We can think of dendrimers as
nanocontainers,” he says, because
of the interior empty space into
which one can put therapeutics.
DNT’s primary goal is to use den-
dritic nanocontainers to transport
toxic therapeutics to disease sites
or cancer tumors while protecting
healthy cells. “It is something like a
Trojan Horse that can be loaded
D
with toxic therapies like cisplatin,
Imethotrexate, or doxorubicin targeted
n
only to the disease site,” says Tom- o
alia, explaining that one can add c
Dspecial surface groups and then di-ect release only in the disease
rea—not throughout the whole
ody. The company is initially fo-
using on cancer treatment and has
tarted the IND drug-application
rocess with a cisplatin-laden drug-
elivery vehicle. The in vivo toxicity
imit for naked cisplatin is approxi-
ately 1 mg per kg of body weight.
ut when cisplatin is disguised in
he interior of a dendrimer, it’s pos-
ible to go up to 15 mg per kg of
ody weight, he says, and thereby
rotect healthy collateral cells yet
till unload a very high localized
oncentration at the disease site.
he company is also collaborating
ith major pharmaceutical compa-
ies to reformulate off-patent drugs
nto similar nanodevices.
“We were amazed to find that
eneration-3, -4, and -5 dendrimers
ave dimensions that are almost
dentical in size to very well-known
roteins,” says Tomalia. For example,
generation-3 PAMAM dendrimer
as dimensions almost identical to
hose of insulin. A generation-5 den-
rimer has almost the same size
nd three-dimensional characteris-
ics of hemoglobin. For these reasons,
omalia and others, including Jon
. Parquette, PhD at Ohio State
niversity and Jean M.J. Fréchet,
hD at the University of California,
erkeley, have pursued research
howing that many dendrimers have
roperties that mimic natural pro-
eins, but they are in fact totally syn-
hetic. “This is where a lot of ex-
itement comes in because when of a gadolinium chelate contrast
endrimer Generations
ncremental synthesis of dendrimers as a function of generation. Dendrimers are spheroid
anoparticles that are precisely engineered to carry molecules encapsulated in the interior
r attached to the surface. Size, shape, and reactivity are determined by generations and
hemical composition, including interior space and surface groups. Graphic supplied by
endritic NanoTechnologies, Inc.injected into an organism, natural
proteins can elicit an immune re-
sponse,” comments Tomalia. “How-
ever, when you inject a dendrimer
of the same size and shape with all
kinds of functionality on the sur-




At recent FDA conferences focused
on the potential of nanotechnology,
Tomalia gave a presentation on the
significance of dendrimers as fun-
damental nanoscale building blocks
and their unique applications as a
function of generation. For example,
generation-7, -8, or -9 dendrimers
may have applications as nano-
scaffolding for gene vectors; gener-
ation-4, -5, or -6 dendrimers may be
useful as nanocontainers in small-
molecule drug delivery. The FDA’s
Center for Drug Evaluation and Re-
search (CDER), in particular, takes
an active position in educating sci-
entists about the unique regulatory
issues nanomedicine presents.
DNT is also pursuing the scaffold-
ing idea to improve diagnostic im-
aging. In 1994, Tomalia, in collabo-
ration with 2003 Nobel laureate and
magnetic resonance imaging (MRI)
researcher Paul C. Lauterbur, PhD
at the University of Illinois and oth-
ers co-published the first paper
showing the importance of den-
drimer scaffolding by demonstrat-
ing that conjugating high multiples
Innovations
501Aagent on the surface of a dendrimer
cproduced the highest relaxivity
Gmeasurements known. Relaxivity is
a technical process used to im-
prove the contrast of MRI images.
The higher the relaxivity, the better
the contrast. The dendrimer-based
imaging product achieved relaxivity
ratings between 40 and 50. By com-
parison, Magnevist, a commercial
chelated gadolinium contrast agent,
has a relaxivity rating of approxi-
mately 4.0–5.0. “With these en-
hanced contrast properties, we have
the potential to detect disease at a
much earlier stage,” says Tomalia.
The past 11 years have seen the
publication of dozens of papers
that used dendrimers as scaffolding
to present MRI contrast agents.
“They have allowed entirely new
in vivo diagnostics of vascular sys-
tems, ischemia, tumor diagnostics
(primary and metastatic) at incredi-
bly high resolutions,” explains Tom-
alia. “You can image things never
possible before.” In September
2004, an NCI/NIH examination of
the 10-year preclinical research his-
tory of dendrimer-based contrast
agents suggested that these mate-
rials are ready for IND approval con-
sideration.
DNT, in collaboration with the MIT
Institute for Soldier Nanotechnolo-
gies and a consortium of other na-
notechnology-inclusive companies
such as Carbon Nanotechnologies,
Inc., Triton Biosystems, Nomadics,
Inc., and Dow Corning are also in-
vestigating the use of dendrimer
nanotechnology innovations to pro-
tect U.S. soldiers in the field. Tom-
alia’s former colleague James Baker
also started NanoProtect, a com-
mercial venture with similar goals.
Baker also founded two other nano-
technology-based entities, NanoBio
Corporation and NanoCure Corpo-
ration. NanoCure, in particular, pur-
sues product pipeline similar to that
of DNT and also applies dendrimer
technology.
Though dendrimers represent only
one approach to nanotechnology,
they appear to hold significant po-
tential as fundamental building
blocks for nanoscale synthesis for
biological and industrial applica-
tions. And DNT, although still a
small, 20-person, privately held
venture, is well positioned to offer
new contributions to the field.lice A. McCarthy (alice@alicemccarthy.
om) is a freelance science writer based in
loucester, MA
